KRAS and inflammatory bowel disease: Meta-analyses suggest flat or invisible lesions in patients without IBD exhibit less KRAS (OR 0.42, CI 0.24-0.72) and APC (OR 0.3, CI 0.19-0.46) mutations compared with polypoid lesions, but with an increased frequency of BRAF mutations (OR 2.2, CI 1.01-4.81) [55].